First Time Loading...

Novartis AG
SIX:NOVN

Watchlist Manager
Novartis AG Logo
Novartis AG
SIX:NOVN
Watchlist
Price: 89.53 CHF -0.52%
Updated: Apr 26, 2024

Intrinsic Value

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. [ Read More ]

The intrinsic value of one NOVN stock under the Base Case scenario is 86.09 CHF. Compared to the current market price of 89.53 CHF, Novartis AG is Overvalued by 4%.

Key Points:
NOVN Intrinsic Value
Base Case
86.09 CHF
Overvaluation 4%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Novartis AG

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling NOVN stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Novartis AG

Provide an overview of the primary business activities
of Novartis AG.

What unique competitive advantages
does Novartis AG hold over its rivals?

What risks and challenges
does Novartis AG face in the near future?

Summarize the latest earnings call
of Novartis AG.

What significant events have occurred
in Novartis AG over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Novartis AG.

Provide P/S
for Novartis AG.

Provide P/E
for Novartis AG.

Provide P/OCF
for Novartis AG.

Provide P/FCFE
for Novartis AG.

Provide P/B
for Novartis AG.

Provide EV/S
for Novartis AG.

Provide EV/GP
for Novartis AG.

Provide EV/EBITDA
for Novartis AG.

Provide EV/EBIT
for Novartis AG.

Provide EV/OCF
for Novartis AG.

Provide EV/FCFF
for Novartis AG.

Provide EV/IC
for Novartis AG.

Show me price targets
for Novartis AG made by professional analysts.

What are the Revenue projections
for Novartis AG?

How accurate were the past Revenue estimates
for Novartis AG?

What are the Net Income projections
for Novartis AG?

How accurate were the past Net Income estimates
for Novartis AG?

What are the EPS projections
for Novartis AG?

How accurate were the past EPS estimates
for Novartis AG?

What are the EBIT projections
for Novartis AG?

How accurate were the past EBIT estimates
for Novartis AG?

Compare the revenue forecasts
for Novartis AG with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Novartis AG and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Novartis AG against its competitors.

Analyze the profit margins
(gross, operating, and net) of Novartis AG compared to its peers.

Compare the P/E ratios
of Novartis AG against its peers.

Discuss the investment returns and shareholder value creation
comparing Novartis AG with its peers.

Analyze the financial leverage
of Novartis AG compared to its main competitors.

Show all profitability ratios
for Novartis AG.

Provide ROE
for Novartis AG.

Provide ROA
for Novartis AG.

Provide ROIC
for Novartis AG.

Provide ROCE
for Novartis AG.

Provide Gross Margin
for Novartis AG.

Provide Operating Margin
for Novartis AG.

Provide Net Margin
for Novartis AG.

Provide FCF Margin
for Novartis AG.

Show all solvency ratios
for Novartis AG.

Provide D/E Ratio
for Novartis AG.

Provide D/A Ratio
for Novartis AG.

Provide Interest Coverage Ratio
for Novartis AG.

Provide Altman Z-Score Ratio
for Novartis AG.

Provide Quick Ratio
for Novartis AG.

Provide Current Ratio
for Novartis AG.

Provide Cash Ratio
for Novartis AG.

What is the historical Revenue growth
over the last 5 years for Novartis AG?

What is the historical Net Income growth
over the last 5 years for Novartis AG?

What is the current Free Cash Flow
of Novartis AG?

Discuss the annual earnings per share (EPS)
trend over the past five years for Novartis AG.

Financials

Balance Sheet Decomposition
Novartis AG

Current Assets 30.5B
Cash & Short-Term Investments 14.1B
Receivables 7.5B
Other Current Assets 8.9B
Non-Current Assets 69.5B
Long-Term Investments 2.8B
PP&E 10.9B
Intangibles 50.2B
Other Non-Current Assets 5.5B
Current Liabilities 26.4B
Accounts Payable 4.9B
Other Current Liabilities 21.5B
Non-Current Liabilities 26.9B
Long-Term Debt 20B
Other Non-Current Liabilities 6.9B
Efficiency

Earnings Waterfall
Novartis AG

Revenue
46.7B USD
Cost of Revenue
-12B USD
Gross Profit
34.6B USD
Operating Expenses
-22B USD
Operating Income
12.6B USD
Other Expenses
2.2B USD
Net Income
14.9B USD

Free Cash Flow Analysis
Novartis AG

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

NOVN Profitability Score
Profitability Due Diligence

Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Free Cash Flow
Positive 3-Year Average ROE
Positive Net Income
67/100
Profitability
Score

Novartis AG's profitability score is 67/100. The higher the profitability score, the more profitable the company is.

NOVN Solvency Score
Solvency Due Diligence

Novartis AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
High Altman Z-Score
Long-Term Solvency
68/100
Solvency
Score

Novartis AG's solvency score is 68/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

NOVN Price Targets Summary
Novartis AG

Wall Street analysts forecast NOVN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NOVN is 98.17 CHF with a low forecast of 74.74 CHF and a high forecast of 115.5 CHF.

Lowest
Price Target
74.74 CHF
17% Downside
Average
Price Target
98.17 CHF
10% Upside
Highest
Price Target
115.5 CHF
29% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

NOVN Price
Novartis AG

1M 1M
+4%
6M 6M
+5%
1Y 1Y
-2%
3Y 3Y
+21%
5Y 5Y
+27%
10Y 10Y
+87%
Annual Price Range
89.53
52w Low
83.23
52w High
94.4
Price Metrics
Average Annual Return 4.22%
Standard Deviation of Annual Returns 8.89%
Max Drawdown -24%
Shares Statistics
Market Capitalization 182.8B CHF
Shares Outstanding 2 044 029 952
Percentage of Shares Shorted
N/A

NOVN Return Decomposition
Main factors of price return

What is price return decomposition?

NOVN News

Other Videos

Last Important Events
Novartis AG

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Novartis AG

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Novartis AG Logo
Novartis AG

Country

Switzerland

Industry

Pharmaceuticals

Market Cap

182.8B CHF

Dividend Yield

3.72%

Description

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Basel, Basel-Stadt and currently employs 104,323 full-time employees. The company went IPO on 2001-05-07. The firm develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The firm uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Contact

BASEL-STADT
Basel
Lichtstrasse 35
+41613241111.0
https://www.novartis.com/

IPO

2001-05-07

Employees

104 323

Officers

Chief Executive Officer
Dr. Vasant Narasimhan M.D.
Chief Financial Officer
Mr. Harry Kirsch
President of US
Mr. Victor Bulto
President of International
Dr. Patrick Horber M.D.
President of Operations
Dr. Steffen Lang Ph.D.
Head of Group Financial Reporting and Accounting
Paul Penepent
Show More
Global Head of Investor Relations
Dr. Samir Shah M.D.
Chief Ethics, Risk & Compliance Officer
Dr. Klaus Moosmayer Ph.D.
Chief Legal Officer
Ms. Karen L. Hale
Chief People & Organization Officer
Dr. Robert Kowalski Pharm.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one NOVN stock?

The intrinsic value of one NOVN stock under the Base Case scenario is 86.09 CHF.

Is NOVN stock undervalued or overvalued?

Compared to the current market price of 89.53 CHF, Novartis AG is Overvalued by 4%.